These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 11309482)

  • 1. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity.
    Flores-Villanueva PO; Yunis EJ; Delgado JC; Vittinghoff E; Buchbinder S; Leung JY; Uglialoro AM; Clavijo OP; Rosenberg ES; Kalams SA; Braun JD; Boswell SL; Walker BD; Goldfeld AE
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5140-5. PubMed ID: 11309482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression.
    Gaudieri S; DeSantis D; McKinnon E; Moore C; Nolan D; Witt CS; Mallal SA; Christiansen FT
    Genes Immun; 2005 Dec; 6(8):683-90. PubMed ID: 16121209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-Bw4-B*57 and Cw*18 alleles are associated with plasma viral load modulation in HIV-1 infected individuals in Salvador, Brazil.
    Silva EM; Acosta AX; Santos EJ; Netto EM; Lemaire DC; Oliveira AS; Barbosa CM; Bendicho MT; Galvão-Castro B; Brites C
    Braz J Infect Dis; 2010; 14(5):468-75. PubMed ID: 21221475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR3DL1-Negative CD8 T Cells and KIR3DL1-Negative Natural Killer Cells Contribute to the Advantageous Control of Early Human Immunodeficiency Virus Type 1 Infection in
    Zhang X; Lu X; Moog C; Yuan L; Liu Z; Li Z; Xia W; Zhou Y; Wu H; Zhang T; Su B
    Front Immunol; 2018; 9():1855. PubMed ID: 30147699
    [No Abstract]   [Full Text] [Related]  

  • 5. Time to seroconversion in HIV-exposed subjects carrying protective versus non protective KIR3DS1/L1 and HLA-B genotypes.
    Tallon BJ; Bruneau J; Tsoukas CM; Routy JP; Kiani Z; Tan X; Bernard NF
    PLoS One; 2014; 9(10):e110480. PubMed ID: 25330014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population.
    López-Vázquez A; Miña-Blanco A; Martínez-Borra J; Njobvu PD; Suárez-Alvarez B; Blanco-Gelaz MA; González S; Rodrigo L; López-Larrea C
    Hum Immunol; 2005 Mar; 66(3):285-9. PubMed ID: 15784466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.
    Martin MP; Gao X; Lee JH; Nelson GW; Detels R; Goedert JJ; Buchbinder S; Hoots K; Vlahov D; Trowsdale J; Wilson M; O'Brien SJ; Carrington M
    Nat Genet; 2002 Aug; 31(4):429-34. PubMed ID: 12134147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort.
    Peterson TA; Kimani J; Wachihi C; Bielawny T; Mendoza L; Thavaneswaran S; Narayansingh MJ; Kariri T; Liang B; Ball TB; Ngugi EN; Plummer FA; Luo M
    Tissue Antigens; 2013 Feb; 81(2):93-107. PubMed ID: 23330720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections.
    Qi Y; Martin MP; Gao X; Jacobson L; Goedert JJ; Buchbinder S; Kirk GD; O'Brien SJ; Trowsdale J; Carrington M
    PLoS Pathog; 2006 Aug; 2(8):e79. PubMed ID: 16933987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption.
    Stern M; Czaja K; Rauch A; Rickenbach M; Günthard HF; Battegay M; Fellay J; Hirschel B; Hess C;
    HIV Med; 2012 Nov; 13(10):589-95. PubMed ID: 22500819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses.
    Gaudieri S; Nolan D; McKinnon E; Witt CS; Mallal S; Christiansen FT
    Mol Immunol; 2005 Feb; 42(4):557-60. PubMed ID: 15607813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
    Ballana E; Riveira-Munoz E; Pou C; Bach V; Parera M; Noguera M; Santos JR; Badia R; Casadellà M; Clotet B; Paredes R; Martínez MA; Brander C; Esté JA
    Immunobiology; 2013 Apr; 218(4):543-7. PubMed ID: 22818666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor.
    Gumperz JE; Barber LD; Valiante NM; Percival L; Phillips JH; Lanier LL; Parham P
    J Immunol; 1997 Jun; 158(11):5237-41. PubMed ID: 9164941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor.
    Gumperz JE; Litwin V; Phillips JH; Lanier LL; Parham P
    J Exp Med; 1995 Mar; 181(3):1133-44. PubMed ID: 7532677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA class I variation in Iranian Lur and Kurd populations: high haplotype and allotype diversity with an abundance of KIR ligands.
    Ashouri E; Norman PJ; Guethlein LA; Han AS; Nemat-Gorgani N; Norberg SJ; Ghaderi A; Parham P
    HLA; 2016 Sep; 88(3):87-99. PubMed ID: 27558013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA and AIDS: a cautionary tale.
    O'Brien SJ; Gao X; Carrington M
    Trends Mol Med; 2001 Sep; 7(9):379-81. PubMed ID: 11530315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.
    Rauch A; Nolan D; Furrer H; McKinnon E; John M; Mallal S; Gaudieri S; Günthard HF; Schmid P; Battegay M; Hirschel B; Telenti A; James I;
    Clin Infect Dis; 2008 Jun; 46(12):1921-5. PubMed ID: 18466093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors.
    Kamya P; Tallon B; Melendez-Pena C; Parsons MS; Migueles SA; Connors M; Miconiatis S; Song R; Boulet S; Bruneau J; Tremblay CL; Bernard NF;
    Clin Immunol; 2012 Jun; 143(3):246-55. PubMed ID: 22445844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.